We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
-0.76%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$185M
AUM Growth
+$125M
Cap. Flow
+$127M
Cap. Flow %
69.01%
Top 10 Hldgs %
67.37%
Holding
37
New
12
Increased
18
Reduced
–
Closed
7

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$16M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.1M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$13.1M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$10.7M
5
INGN icon
Inogen
INGN
+$10.5M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$3.4M
2
ILMN icon
Illumina
ILMN
+$2.58M
3
HRTX icon
Heron Therapeutics
HRTX
+$1.66M
4
PEN icon
Penumbra
PEN
+$1.65M
5
CVS icon
CVS Health
CVS
+$1.02M

Sector Composition

Rank Sector Weight
1 Healthcare 89.71%
2 Industrials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.5B
$18.7M 10.13%
730,440
+575,553
+372% +$16M
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$16.5M 8.95%
314,217
+228,556
+267% +$13.1M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$11.5B
$15.1M 8.18%
+176,325
New +$15.1M
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$14.3M 7.72%
525,730
+341,828
+186% +$10.7M
INGN icon
5
Inogen
INGN
$178M
$12.8M 6.94%
191,970
+138,395
+258% +$10.5M
PTCT icon
6
PTC Therapeutics
PTCT
$6.52B
$12.6M 6.84%
280,542
+127,714
+84% +$5.04M
GILD icon
7
Gilead Sciences
GILD
$167B
$10M 5.43%
148,281
+78,402
+112% +$5.16M
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$15.5B
$9.12M 4.94%
+63,940
New +$8.59M
CNC icon
9
Centene
CNC
$32.8B
$7.74M 4.19%
147,638
+88,545
+150% +$4.78M
UNH icon
10
UnitedHealth
UNH
$387B
$7.51M 4.07%
30,767
+19,903
+183% +$4.79M
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$6.35M 3.44%
126,655
+64,094
+102% +$3.12M
NTRA icon
12
Natera
NTRA
$38.9B
$6.01M 3.25%
217,899
+187,441
+615% +$4.14M
CBIO
13
Crescent Biopharma
CBIO
$526M
$5.94M 3.21%
4,980
+3,610
+264% +$4.32M
TWST icon
14
Twist Bioscience
TWST
$5.84B
$4.99M 2.7%
171,903
+148,170
+624% +$3.92M
ELV icon
15
Elevance Health
ELV
$80.9B
$4.68M 2.53%
+16,581
New +$4.53M
CRSP icon
16
CRISPR Therapeutics
CRSP
$4.71B
$4.59M 2.49%
+97,499
New +$3.9M
OPK icon
17
Opko Health
OPK
$899M
$3.97M 2.15%
+1,628,666
New +$3.55M
VRAY
18
DELISTED
ViewRay, Inc.
VRAY
$3.91M 2.12%
443,973
+360,362
+431% +$2.93M
PCRX icon
19
Pacira BioSciences
PCRX
$1.01B
$3.69M 2%
84,735
+70,854
+510% +$3.01M
XLRN
20
DELISTED
Acceleron Pharma
XLRN
$3.39M 1.83%
82,473
+52,348
+174% +$2.17M
AVTR icon
21
Avantor
AVTR
$7.56B
$2.35M 1.27%
+122,962
New +$2.19M
NCNA
22
NuCana
NCNA
$5.47M
$1.69M 0.91%
32
+23
+256% +$1.58M
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.82B
$1.68M 0.91%
+11,050
New +$1.34M
VRCA icon
24
Verrica Pharmaceuticals
VRCA
$96M
$1.54M 0.84%
13,282
+6,236
+89% +$585K
IRTC icon
25
iRhythm Holdings
IRTC
$3.64B
$1.18M 0.64%
14,854
+3,876
+35% +$282K
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Asymmetry Capital Management held 37 positions worth $185M, up 209% from $59.8M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Asymmetry Capital Management deployed $127M of net new capital in Q2 2019, opening 12 new positions and adding to 18 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 176,325 shares worth $15.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 83% a quarter earlier, followed by Industrials.

On the sell side, the most notable exit was Aerie Pharmaceuticals, an estimated $3.4M sold.

  • Asymmetry Capital Management's largest Q2 2019 buy was BioMarin Pharmaceuticals: 176,325 shares worth $15.1M.
  • Asymmetry Capital Management added most to Insmed in Q2 2019, an estimated $16M increase.
  • Asymmetry Capital Management fully exited Aerie Pharmaceuticals in Q2 2019, selling an estimated $3.4M.
  • Asymmetry Capital Management's ten largest holdings make up 67% of its $185M portfolio in Q2 2019.
  • Asymmetry Capital Management opened 12 new positions and closed 7 in Q2 2019.
  • Asymmetry Capital Management's portfolio value rose 209% quarter-over-quarter to $185M.

Based on Asymmetry Capital Management's 13F filing for Q2 2019, filed 7 Aug 2019.